Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease.

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49

Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord (2010) 9.34

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet (2014) 3.44

MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord (2015) 3.25

Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60

Pharmacological treatment of Parkinson disease: a review. JAMA (2014) 2.43

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09

Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord (2007) 1.96

A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology (2008) 1.74

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain (2014) 1.74

Parkin disease: a clinicopathologic entity? JAMA Neurol (2013) 1.68

Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol (2010) 1.50

Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord (2013) 1.41

Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport (2006) 1.37

Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain (2010) 1.34

Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem (2009) 1.27

The motor phenotype of Parkinson's disease in relation to age at onset. Mov Disord (2011) 1.20

T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord (2011) 1.14

Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol (1998) 1.10

Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. Biochem Biophys Res Commun (1998) 1.09

Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain (2007) 1.05

Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci (2011) 0.92

Neuromelanin magnetic resonance imaging in Parkinson's disease and multiple system atrophy. Eur Neurol (2013) 0.89

Initial management of Parkinson's disease. BMJ (2014) 0.84

Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord (2014) 0.84

Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov Disord (2015) 0.83

The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1. AJNR Am J Neuroradiol (2014) 0.81

Recessive Parkinson's disease. Mov Disord (2006) 0.80

Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. Eur J Neurol (2014) 0.80

A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson's disease. Neurosci Lett (2016) 0.79

Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease. Neurobiol Aging (2014) 0.77

Twenty years since the discovery of the parkin gene. J Neural Transm (Vienna) (2017) 0.75